CASE REPORT

Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone

Nozomi Okahashi¹, Masayuki Kubo², Ei Hoshino¹, Masahito Uchihara¹, Itsuto Amano² and Haruyuki Tanaka²

Abstract:
Pure red cell aplasia (PRCA) associated with erythropoiesis-stimulating agents (ESAs), which were first reported in 1998, usually occurs with subcutaneous administration of epoetin alfa (Eprex⁵). Improvements in ESA storage, handling, and administration methods have reduced the PRCA incidence. Continuous erythropoietin receptor activator (CERA) is a third-generation ESA that is rarely reported to induce PRCA. We herein report a case of CERA-induced PRCA presenting with positive anti-erythropoietin (EPO) and anti-CERA antibodies, which was successfully treated with prednisolone. Clinicians should be aware of the possibility of antibody-mediated PRCA induced by an ESA in CKD patients with anemia with reticulocytopenia and low serum EPO levels.

Key words: antibody-mediated pure red cell aplasia, continuous erythropoietin receptor activator, erythropoiesis-stimulating agents, anti-erythropoietin antibody, anti-CERA antibody

(Intern Med 61: 2209-2213, 2022) (DOI: 10.2169/internalmedicine.8823-21)

Introduction
Erythropoiesis-stimulating agents (ESAs) are widely used to treat renal anemia in patients with chronic kidney disease (CKD). Antibody-mediated pure red cell aplasia (PRCA) associated with the use of ESAs was first reported in 1998, with several cases reported thereafter (1, 2). Most cases of PRCA occurred in patients who received epoetin alfa (Eprex⁵) subcutaneously; this method of administration was considered more likely to evoke an immune response than intravenous administration (3). Improvements in the storage and administration of epoetin alfa have resulted in a decrease in the incidence of PRCA in patients with CKD (3).
Continuous erythropoietin receptor activator (CERA) is a third-generation ESA with a methoxy-polyethylene glycol polymer chain integrated into the erythropoietin molecule and a longer elimination half-life than previous ESAs (4). Few cases of PRCA induced by CERA and presenting with anti-epoetin beta pegol antibody have been reported (5, 6).

We herein report a case of PRCA induced by CERA, presenting with both anti-erythropoietin (EPO) and anti-CERA antibodies and successfully treated with prednisolone (PSL).

Case Report
A 69-year-old man with stage 4 CKD due to immunoglobulin A (IgA) nephropathy was started on monthly subcutaneous CERA (Mircera⁶) as a treatment for renal anemia with a hemoglobin (Hb) level of approximately 10 g/dL. He initially responded well to CERA with a Hb level of approximately 12 g/dL. However, 7 months after the initiation of CERA therapy, his Hb level suddenly decreased to 6.7 g/dL, and the patient fainted when standing up. He was therefore admitted to our hospital. Other notable results were a low reticulocyte count (2,170/μL), normal white blood cell (WBC) count (5,100/μL) with normal differentials, and low platelet count (94×10³/μL). The platelet count was low at 116×10³/μL before the initiation of CERA. His serum EPO level decreased to below detection limit (Table 1). Gastroin-
testicular endoscopy revealed no bleeding site, and fecal occult blood test results were negative. A bone marrow aspiration smear revealed the absence of erythroblasts with other normal lineages, consistent with PRCA (Fig. 1). Results of serological tests for parvovirus B19 immunoglobulin M (IgM), cytomegalovirus IgM, Epstein Barr virus capsid antigen IgM, and antinuclear antibodies were negative. Systemic computed tomography (CT) did not reveal a thymoma, malignant lymphoma, or other malignant tumors. Discontinuation of his regular medications (sitagliptin, pitavastatin, lan-

| Table 1. Laboratory Data at Admission. |
|----------------------------------------|
| **Peripheral blood** | **Biochemistry** | **Immunoserology** |
| WBC 5,100 μL | TP 6.2 g/dL | IgG 889 mg/dL |
| Stab 5 % | Alb 4.0 g/dL | IgA 177 mg/dL |
| Seg 53 % | AST 20 IU/L | | |
| Lym 27 % | ALT 18 IU/L | | |
| Mono 7 % | LDH 146 IU/L | | |
| Eo 8 % | ALP 104 IU/L | | |
| Baso 0 % | γ-GTP 16 IU/L | | |
| RBC 217 ×10^12/μL | T-Bil 1.1 mg/dL | | |
| Hb 6.7 g/dL | D-Bil 0.1 mg/dL | | |
| Ht 19.6 % | Glu 118 mg/dL | Parvovirus B19 IgM (EIA) 0.57 |
| MCV 90.3 fL | UA 8.8 mg/dL | CMV IgM (EIA) 0.18 |
| Ret 0.1 % | BUN 72 mg/dL | CMV IgG (EIA) 9.1 |
| Plt 94 ×10^11/μL | Cr 3.64 mg/dL | | |
| eGFR 14.1 mL/min | | EBV VCA IgM (FA) ×100 |
| CRP 0.01 mg/dL | | EBV VCA IgG (FA) ×100 |
| EPO <0.6 mIU/mL | | |

WBC: white blood cell, Stab: stab cell, Seg: segmental cell, Lym: lymphocyte, Mono: monocyte, Eo: eosinophil, Baso: basophil, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, MCV: mean corpuscular volume, Ret: reticulocytes, Plt: platelet, TP: total protein, Alb: albumin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyltransferase, T-Bil: total bilirubin, D-Bil: direct bilirubin, Glu: glucose, UA: uric acid, BUN: blood urea nitrogen, Cr: creatinine, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein, EPO: erythropoietin, IgG: immunoglobulin G, IgA: immunoglobulin A, IgM: immunoglobulin M, C3: complement 3, C4: complement 4, CH50: complement titer (CH50, 50% hemolytic unit of complement), ANA: antinuclear antibodies, DAT: direct antitubulin test, CMV: cytomegalovirus, EBV: Epstein Barr virus, VCA: viral capsid antigen, EIA: enzyme immunoassay, FA: fluorescent antibody

futidine, irbesartan, febuxostat, and minodronic acid) for three weeks did not improve the anemia. Based on these results, PRCA induced by CERA was suspected. Subsequently, results from serological studies confirmed the presence of anti-EPO and anti-CERA antibodies [anti-EPO: 1.7110 titer (normal range <0.0815), anti-CERA: 0.0510 titer (normal range <0.0195)]. An examination was performed using an enzyme-linked immunosorbent assay (ELISA) by Chugai Pharmaceutical, Japan. Based on these results, the patient was diagnosed with antibody-mediated PRCA induced by CERA.

The patient’s anemic condition did not improve despite discontinuation of CERA on admission; therefore, he was administered immunosuppressive therapy. As the patient had diabetes mellitus, we started treatment with cyclosporine (CyA) rather than corticosteroids (CSs). CyA was started at 100 mg/day and adjusted to maintain a trough concentration between 150 and 250 ng/mL.

However, 3 months after the start of CyA, his reticulocyte count and Hb level did not increase, and he required weekly blood transfusions to maintain a target Hb 7.0 g/dL level. Therefore, the treatment was switched to oral PSL alone at 50 mg per day (1 mg/kg) with insulin therapy. After 24 days, laboratory tests revealed an increased reticulocyte count of 23,900/μL and Hb level of 8.4 g/dL, and he did not require further blood transfusions. The serum EPO level also increased to 68.4 mIU/mL. After 2 weeks of the initial dose, PSL was reduced by 5 mg every week. After reducing the

Figure 1. Bone marrow aspiration smear. A bone marrow aspiration smear showed the absence of erythroblasts with normal myeloid cells and megakaryocytes (May-Giemsas staining, 400-fold).
dose of PSL to 25 mg, it was reduced by 5 mg every 3 weeks. Three months after the initiation of PSL treatment, levels of anti-EPO and anti-CERA antibodies were undetectable, and his Hb level has remained at approximately 11 g/dL with 5 mg/day PSL (Fig. 2).

Discussion

PRCA is a rare syndrome characterized by severe normochromic normocytic anemia associated with reticulocytopenia and the absence of erythroblasts from otherwise normal bone marrow (7). PRCA is a primary hematologic disorder, but it can also occur secondary to infections (especially parvovirus B19), hematologic malignancies, autoimmune diseases, thymoma, and exposure to drugs and toxic agents (8).

The incidence of PRCA associated with anti-EPO antibodies in CKD patients with anemia treated with ESAs began to increase in 1998 and peaked in 2001 (3). Most of these cases were in patients who were administered epoetin alfa (Eprex®) subcutaneously, and it is thought that polysorbate-80 from uncoated rubber syringe stoppers caused PRCA associated with epoetin alfa (9, 10). In the case of PRCA induced by ESAs, the development of neutralizing anti-EPO antibodies, which recognize all available ESAs as well as endogenous EPO, blocks the interaction between EPO and its receptor (2). The mean interval between initiating ESA therapy and the onset of PRCA was 9 (range, 2-63) months (9).

Recently, the incidence of PRCA induced by ESAs has decreased owing to improvements in the storage of ESAs and in the route of administration (3, 10). CERA, a third-generation ESA approved in 2007, has a methoxy-polyethylene glycol polymer chain integrated into the erythropoietin molecule and a prolonged half-life (approximately 130 hours), allowing for extended dosing intervals (every 2 or 4 weeks) (11). This agent is generally well tolerated, with most adverse events being of mild to moderate severity (11), but there are a few case reports of PRCA related to CERA (5, 6) (Table 2). In addition, darbepoetin alfa, another ESA, is also widely used for renal anemia in patients with CKD, and several cases of antibody-mediated PRCA have been reported (12-16). In almost all cases, ESAs were administered subcutaneously, and immunosuppressive therapy was required (Table 2).

Treatment of antibody-mediated PRCA induced by ESAs generally requires discontinuation of ESAs and administration of immunosuppressive agents such as CyA and CS to suppress anti-EPO antibodies (2). The response rates to CyA and CS in patients with anti-EPO antibody-mediated PRCA were 67% and 56%, respectively (17). In our case, initial CyA therapy did not improve the hematological parameters of PRCA, so consequently, CS therapy was started. CS plus cyclophosphamide (CY) is also an effective therapy with a response rate of 87% (17), and we considered this as a secondary option if CS therapy proved ineffective. Successful re-treatment with ESAs in patients with detectable antibodies has been described, but this is associated with a high risk of exacerbation and is generally not recommended (8, 18). Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have been used to treat renal anemia. HIF-PHIs promote erythropoiesis primarily through increased endogenous EPO production and modulation of iron metabolism (19). Recently, antibody-mediated PRCA treated with roxadustat has been reported (20, 21). In one case, roxadustat was administered as re-treatment for renal anemia after immunosuppressive therapy (20). In another case, roxadustat was administered instead of immunosuppressive
therapy, which improved PRCA (21). It is speculated that endogenous EPO upregulated by roxadustat helped neutralize anti-EPO antibodies but not boost the formation of antibodies to EPO (21). HIF-PHIs may thus be a safe option for treating renal anemia in patients with antibody-mediated PRCA.

Although the incidence of PRCA is decreasing, as described above, it remains an important complication in patients with CKD using ESAs. The reticulocyte count helps in the early diagnosis of PRCA during ESA treatment in patients with CKD. Furthermore, in PRCA not related to EPO antibodies, serum EPO levels increase as a result of the reduced consumption of EPO by erythroblasts, whereas in PRCA caused by neutralizing antibodies to EPO, serum EPO levels are usually extremely low (9). Anemia with both reticulocytopenia and low serum EPO levels indicates antibody-mediated PRCA in patients treated with ESAs. Clinicians should recognize that CERA, like other ESAs, induces antibody-mediated PRCA, and PRCA should be considered in the differential diagnosis of ESA-refractory anemia in patients with CKD.

The authors state that they have no Conflict of Interest (COI).

References
1. Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and anterythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002.
2. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 3: 193-199, 2008.
3. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351: 1403-1408, 2004.
4. Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (continuous erythropoietin receptor activator). Int J Nanomedicine 2: 33-38, 2007.
5. Hirai K, Okawara S, Miyazawa H, et al. Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. CEN Case Rep 5: 78-82, 2016.
6. Shingu Y, Nakata T, Sawai S, et al. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient. BMC Nephrol 21: 275, 2020.
7. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142: 505-514, 2008.

8. Means RT Jr. Pure red cell aplasia. Hematology Am Soc Hematol Educ Prog 2016: 51-56, 2016.

9. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 18: viii37-viii41, 2003.

10. Bennett CL, Starko KM, Thomsen HS, et al. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. A report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 27: 1697-1703, 2012.

11. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 68: 1139-1156, 2008.

12. Sia CS, Jen WY, Poon ML. Acquired antibody-mediated pure red cell aplasia following treatment with darbepoetin. Ann Acad Med Singapore 49: 46-48, 2020.

13. Howman R, Kulkami H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 22: 1462-1464, 2007.

14. Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 30: 451-460, 2015.

15. Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant 21: 2963-2965, 2006.

16. Padhi S, Behera G, Pattnaik SA, Das PK, Adhya AK, Patra S. Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy. Indian J Nephrol 30: 113-116, 2020.

17. Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363: 1768-1771, 2004.

18. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 20: 23-26, 2005.

19. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl 11: 8-25, 2021.

20. Wu Y, Cai X, Ni J, Lin X. Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat. Int J Lab Hematol 42: e291-e293, 2020.

21. Wan K, Yin Y, Lao Z, Cheng J. Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. Ann Hematol 100: 591-593, 2021.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2022 The Japanese Society of Internal Medicine

Intern Med 61: 2209-2213, 2022 DOI: 10.2169/internalmedicine.8823-21